Earnings call transcript: Sensirion lifts H1 2026 sales, shares fall 14%

EBOS Group reported a 9.9% increase in full-year revenue to AUD 13.5 billion for FY 2026, while underlying EBITDA rose 5.0% to AUD 614 million, both remaining within guidance. The company delivered a resilient year, despite challenges from fuel, currency, and competition. The healthcare division led the growth, with revenue up 8.5% and EBITDA up 3.2%.

The animal care division showed the strongest growth, with revenue up 34.6% and EBITDA up 11.6%. Management highlighted the completion of a multiyear distribution center renewal program, with the Kemps Creek facility in New South Wales operating 20% more productively than its predecessor. Despite the progress, EBOS shares rose 5.5% to $23, still below its 52-week high of $41.49.

Analysts noted that while the company's results were in line with expectations, the profit growth remained limited due to margin pressures. The stock appears overvalued, according to InvestingPro analysis, and investors should exercise caution despite the recent rally. EBOS forecasted FY 2027 underlying EBITDA to range from AUD 635 million to AUD 655 million, with a midpoint of AUD 645 million.

The company expects lower capital expenditure, which is anticipated to fall to AUD 100 million from AUD 145 million in FY 2026, to support growth projects and improve free cash flow. CEO Adam Hall emphasized that the company has completed a major phase of investment and is now well-placed to reduce leverage while continuing to fund growth initiatives.